Muscle & Myokines: How Strength Training Fights Aging

Quick answer: Skeletal muscle is the largest endocrine organ in the body, releasing over 600 signaling proteins called myokines during contraction — including irisin (drives BDNF and fat browning), IL-6 (anti-inflammatory at exercise levels), BDNF (hippocampal neurogenesis), and FSTL-1 (cardiac protection). Grip strength is a stronger predictor of all-cause mortality than blood pressure in multiple large cohort studies. The EWGSOP2 criteria define sarcopenia as low muscle mass + reduced strength or physical performance — affecting 10% of adults over 60 and 50% over 80.

Muscle: Far More Than Movement

The prevailing understanding of skeletal muscle as a passive mechanical actuator — tissue that contracts when signaled, moves bones, and burns fuel — is fundamentally incomplete. The discovery of myokines over the past two decades has established muscle as a major endocrine organ that communicates continuously with every organ system in the body through exercise-induced cytokines and peptides.

Muscle tissue constitutes 30–40% of body mass in healthy adults — the largest organ by mass in non-obese individuals. When contracted by exercise, muscle releases hundreds of bioactive peptides directly into the circulation, producing systemic effects on the brain (BDNF, irisin), adipose tissue (irisin-driven browning, lipolysis), bone (IGF-1, irisin), liver (FGF21, IL-6), immune system (IL-6, IL-15), cardiovascular system (FSTL-1, apelin), and gut microbiome (secondary bile acid changes from exercise). Exercise is, in effect, the administration of a complex drug cocktail — with muscle as the pharmacy.

This myokine signaling network explains a longstanding puzzle: why does exercise benefit virtually every organ system simultaneously, produce anti-cancer, anti-inflammatory, pro-cognitive, and cardiovascular effects that no single pharmaceutical can replicate? The answer is that exercise doesn’t target one system — it activates the entire myokine endocrine network, producing coordinated multi-system benefits that evolved over millions of years of obligate physical activity in our ancestors.

Key Myokines and Their Functions

Irisin: The Exercise Factor for Brain and Fat

Irisin, identified by Bruce Spiegelman’s Harvard laboratory in 2012 (Nature), is cleaved from FNDC5 (fibronectin type III domain-containing protein 5) expressed in muscle during aerobic and resistance exercise via PGC-1α activation. Irisin circulates to multiple target tissues:

In adipose tissue, irisin stimulates the browning of white adipose to beige adipose — upregulating UCP1 (uncoupling protein 1) and increasing thermogenic capacity and resting metabolic rate. This mechanism explains part of the metabolic benefit of exercise beyond acute caloric expenditure.

In the brain, irisin crosses the blood-brain barrier and stimulates BDNF (brain-derived neurotrophic factor) expression in the hippocampus — producing the same neuroplasticity and neurogenesis stimulus responsible for exercise’s cognitive benefits. Studies by Vaynman, Ying, and Gomez-Pinilla (UCLA) demonstrated that blocking irisin/FNDC5 abolishes the cognitive benefits of running in mice. Human studies: exercise training increases serum irisin by 10–20%, and higher irisin levels correlate with better cognitive performance, smaller hippocampal atrophy, and lower Alzheimer’s risk in prospective cohorts.

In bone, irisin increases osteoblast activity and reduces osteoclast activity — producing net bone formation. This mechanism partly explains why weight-bearing exercise is the most effective intervention for maintaining bone mineral density beyond HRT or bisphosphonates in terms of mechanism.

IL-6: Anti-Inflammatory at Exercise Doses

Interleukin-6 (IL-6) is primarily known as a pro-inflammatory cytokine released from macrophages and adipose tissue in chronic disease. Exercise-derived IL-6 is paradoxically anti-inflammatory — the same molecule with different effects depending on context, concentration, and co-signals.

During moderate exercise, contracting muscle releases IL-6 at concentrations 100-fold above resting levels — but in a pulsatile, transient pattern without the co-elevation of TNF-α that characterizes inflammatory IL-6. Exercise-derived IL-6 drives AMPK activation, fat oxidation, glucose uptake in muscle, and — crucially — stimulates the release of anti-inflammatory IL-10 and IL-1ra (IL-1 receptor antagonist) from the liver and immune cells, creating a net anti-inflammatory cascade. This explains why regular exercisers have lower chronic inflammatory markers (hsCRP, IL-6 at rest, TNF-α) despite transiently raising IL-6 during each exercise bout.

IL-15: Muscle–Immune Crosstalk and Natural Killer Cells

IL-15, released by contracting muscle, is a primary driver of natural killer (NK) cell proliferation and cytotoxic activity. NK cells are the immune system’s first-line cancer surveillance agents — recognizing and eliminating cells expressing oncogenic surface signals before they establish clinical tumors. Exercise-induced IL-15 amplifies NK cell numbers and killing capacity, providing a mechanistic link between exercise and the consistent 10–20% cancer risk reduction observed across 26 cancer types in large prospective studies (Moore et al., 2016, JAMA Internal Medicine).

IL-15 also drives anti-senescent NK cell activity — senescent cells, which display NKG2D ligands on their surface, are recognized and eliminated by NK cells in an IL-15-dependent manner. This provides a direct mechanism linking muscle-generated IL-15 to senescent cell clearance — exercise as a physiological senolytic. A study by Duggal et al. (2018, Aging Cell) found that master-level cyclists in their 60s–80s had NK cell profiles resembling 20-year-olds, with dramatically lower senescent cell burden than sedentary age-matched controls.

FSTL-1: The Cardiac Protector

Follistatin-like protein 1 (FSTL-1), released by contracting muscle and heart during exercise, acts as a cardiomyocyte survival factor — reducing ischemia-reperfusion injury and stimulating cardiac progenitor cell proliferation. Bostrom et al. (2011, Cell) identified FSTL-1 as the active cardioprotective factor in conditioned medium from exercised hearts. This mechanism partly explains why exercise training reduces myocardial infarction size and post-MI cardiac dysfunction, and why physically active individuals have better cardiac outcomes after myocardial infarction than sedentary individuals with identical infarct sizes.

Myostatin: The Muscle Growth Brake

Myostatin (GDF-8) is a negative regulator of muscle mass — suppressing satellite cell proliferation and muscle fiber hypertrophy. Myostatin expression increases with aging, immobilization, and glucocorticoid excess, contributing to sarcopenia. Exercise — particularly resistance training — reduces myostatin expression in skeletal muscle. Myostatin deficiency in mice and cattle produces extraordinary muscle hypertrophy (the “double-muscled” phenotype). Rare human myostatin loss-of-function mutations produce extraordinary childhood muscle development without apparent adverse effects. Pharmacological myostatin inhibitors (follistatin, bimagrumab) are in clinical trials for sarcopenia treatment and cancer-associated muscle wasting (cachexia).

Sarcopenia: Definition, Diagnosis, and Consequences

Sarcopenia — age-related loss of skeletal muscle mass, strength, and function — is formally recognized as a disease by ICD-10 (M62.84) since 2016. The European Working Group on Sarcopenia in Older People 2 (EWGSOP2, Cruz-Jentoft 2019) defines sarcopenia by:

Probable sarcopenia: Low muscle strength (grip strength <27 kg men, <16 kg women; or chair-stand >15 seconds for 5 repetitions).

Confirmed sarcopenia: Low muscle strength + low muscle mass (DEXA: appendicular skeletal muscle mass index <7.0 kg/m² men, <5.5 kg/m² women; or BIA with sex-specific thresholds).

Severe sarcopenia: Low muscle strength + low muscle mass + low physical performance (gait speed ≤0.8 m/s or Short Physical Performance Battery score ≤8).

Sarcopenia prevalence: approximately 10% of community-dwelling adults over 60, rising to 50% of those over 80. The mortality data is striking: in a meta-analysis of 35 studies (Shafiee et al., 2017, Journal of the American Medical Directors Association), sarcopenia was associated with a 2-fold increase in all-cause mortality, independent of age and comorbidities. Low grip strength specifically is a stronger predictor of all-cause mortality than blood pressure or resting heart rate across multiple large cohort studies (Leong et al., 2015, The Lancet, n=139,691 across 17 countries: each 5 kg reduction in grip strength was associated with 17% increased all-cause mortality).

Measuring Muscle Mass and Function

DEXA (Dual-Energy X-ray Absorptiometry): Gold standard for body composition — measures lean mass, fat mass, and bone mineral density. Appendicular skeletal muscle mass (ASM = sum of arm + leg lean mass) indexed to height² (ASMI) is the standard sarcopenia diagnostic metric. DEXA also measures visceral adipose tissue (VAT) — an independent cardiovascular and metabolic risk factor. Cost: $50–$200, available at many imaging centers and some physician offices.

Bioelectrical Impedance Analysis (BIA): Uses electrical resistance differences between muscle (high water content, low resistance) and fat (low water content, high resistance) to estimate body composition. Consumer devices (InBody 270/570, Tanita, Withings Body+) provide reasonable estimates for longitudinal tracking. Medical-grade InBody (hospital-level devices) has accuracy approaching DEXA for muscle mass. Standard bathroom scale BIA devices have significant error and are not appropriate for clinical decision-making.

Grip strength (hand dynamometer): Smedley or Jamar hand dynamometer measures maximal isometric grip force. Takes 30 seconds, costs under $50, and has stronger mortality prediction than most blood biomarkers. Should be measured seated, elbow at 90°, three trials each hand, using the maximum value. Norms are age, sex, and height-adjusted.

Gait speed: Time to walk 4 or 6 meters at usual pace. Under 0.8 m/s = functional limitation threshold; under 1.0 m/s = increased mortality risk. Takes 60 seconds in any hallway. Every 0.1 m/s increase in gait speed is associated with 12% reduction in mortality in older adults (Studenski et al., 2011, JAMA).

Chair stand test (30-second): Count repetitions of sit-to-stand from a chair in 30 seconds. Less than 12 repetitions for ages 60–64 indicates significantly impaired lower extremity strength and increased fall risk. This test assesses functional muscle power (force × velocity) rather than maximal isometric strength.

Resistance Training for Longevity: Evidence-Based Protocols

The meta-analytic evidence for resistance training mortality benefit is now as strong as for aerobic exercise. A 2022 meta-analysis in the British Journal of Sports Medicine (Momma et al.) of 16 prospective cohort studies (n=1,544,336) found that muscle-strengthening activities 1–2 times per week were associated with a 10–17% reduction in all-cause mortality, cardiovascular mortality, cancer mortality, and diabetes risk — independently of aerobic activity. Combined aerobic + resistance training produced larger mortality reductions than either alone (29% vs. 19% for aerobic alone).

Progressive overload principle: The fundamental driver of muscle hypertrophy and strength gain. Muscle must be consistently challenged with increasing resistance, volume, or complexity to maintain adaptational stimulus. Maintaining the same workout at the same weight year after year produces maintenance at best — not progression.

Training parameters for hypertrophy (muscle building): 3–5 sets per exercise, 6–12 repetitions per set, 60–75% of 1-repetition maximum (1RM), 60–90 second rest intervals between sets. Compound movements (squat, deadlift, hip hinge, vertical push/pull, horizontal push/pull) build the most muscle per unit of time by activating large, multi-joint movement patterns. Frequency: each major muscle group trained 2x per week minimum for hypertrophy optimization.

Training parameters for strength and power: 3–5 sets per exercise, 2–6 repetitions per set, 80–95% 1RM, 2–5 minute rest intervals. Strength training (high load, low rep) produces superior neuromuscular adaptations — particularly relevant for older adults where neural efficiency and fast-twitch fiber recruitment are the primary functional limitations. Power training (lighter loads, maximal velocity) is increasingly recognized as important for fall prevention — the ability to generate force rapidly is what determines whether a stumble becomes a fall.

Protein timing and dosing: Muscle protein synthesis requires leucine threshold activation — approximately 2–3g leucine per meal to maximally stimulate mTORC1-dependent MPS. This corresponds to approximately 25–40g of high-quality protein per meal (whey, eggs, meat, fish) depending on leucine content. Protein dose at bedtime (40g slow-digest casein) has been specifically validated for overnight muscle protein synthesis by Res et al. (2012, Medicine & Science in Sports & Exercise). Total daily protein target for muscle preservation in adults over 50: 1.2–1.6 g/kg/day (higher than the RDA of 0.8 g/kg, which prevents deficiency but does not optimize anabolic response in aging muscle).

Anabolic Resistance: Why Older Muscle Doesn’t Respond as Well

A fundamental challenge in longevity medicine is anabolic resistance — the reduced sensitivity of aging muscle to the anabolic stimuli of protein and exercise. Older adults require more protein per meal (30–40g versus 20–25g) and more training stimulus to achieve the same muscle protein synthesis response as younger adults. The mechanisms include: reduced mTORC1 sensitivity to leucine, impaired insulin signaling in aged muscle, reduced satellite cell proliferative capacity, increased myostatin expression, and systemic low-grade inflammation (inflammaging) that suppresses anabolic pathways.

Evidence-based approaches to overcome anabolic resistance include: higher protein doses per meal (30–40g), leucine supplementation (2–3g free leucine with each protein meal to ensure threshold activation even with lower-protein meals), HMB (beta-hydroxy-beta-methylbutyrate, 3g/day — a leucine metabolite with direct mTORC1 activation and anti-catabolic effects; strongest evidence in older adults with limited training capacity), creatine monohydrate (3–5g/day — the most extensively studied ergogenic aid, improves muscle mass, strength, and high-intensity performance in older adults with high safety profile), and resistance training itself (the most potent anti-anabolic resistance intervention available).

FAQs About Muscle, Myokines, and Sarcopenia

At what age does muscle loss become clinically significant?
After peak muscle mass at approximately age 25–30, adults lose 3–8% of muscle mass per decade under sedentary conditions, accelerating to 15% per decade after age 70. Functionally significant sarcopenia becomes clinically apparent most commonly in the 60s and 70s — but the underlying muscle loss trajectory begins in the 30s. This means the most impactful intervention window is the 40s–60s, when the loss rate is meaningful but full sarcopenia has not yet developed. Starting a consistent resistance training program at 40 is vastly more effective than starting at 70 from a prevention standpoint, though meaningful muscle gain remains achievable at any age — studies demonstrate significant hypertrophy from resistance training even in nonagenarians.

Can you build significant muscle after 60?
Yes — multiple randomized controlled trials confirm meaningful muscle hypertrophy from resistance training in adults aged 60–90. Fiatarone et al. (1990, JAMA) demonstrated that high-intensity resistance training (80% 1RM) in 90-year-old nursing home residents produced 174% increases in muscle strength and 9% increases in mid-thigh muscle cross-sectional area in just 8 weeks. The anabolic response is blunted compared to young adults but is substantial and clinically significant. The key requirements: progressive overload (training must become harder over time), adequate protein (1.2–1.6 g/kg/day with 30–40g per meal), creatine supplementation (3–5g/day), and consistency (2–3x per week minimum).

Is grip strength really a better predictor than blood pressure?
Multiple large studies confirm grip strength is at least as powerful as blood pressure as a mortality predictor — and in some analyses, stronger. The PURE study (Leong et al., 2015, The Lancet, n=139,691 across 17 countries) found each 5 kg reduction in grip strength was associated with a 17% increase in all-cause mortality, 17% increase in cardiovascular mortality, and 9% increase in non-cardiovascular mortality — with grip strength being a stronger predictor of these outcomes than systolic blood pressure in the same dataset. Grip strength serves as a proxy for overall muscle mass, neuromuscular health, and systemic anabolic status — making it an integrative biomarker comparable to VO2max in its predictive scope.

How do myokines explain why exercise helps depression and anxiety?
Multiple mechanisms connect exercise-generated myokines to mental health. Irisin from muscle drives BDNF expression in the hippocampus — BDNF is required for the neurogenesis and synaptic plasticity that antidepressants (particularly SSRIs) partially restore through different upstream mechanisms. Exercise-derived IL-6 reduces systemic inflammation — and neuroinflammation is increasingly recognized as a primary driver of treatment-resistant depression. The locus coeruleus (norepinephrine center) receives dense vagal afferent input and BDNF support from exercise — producing the norepinephrine increase associated with antidepressant effect. Running specifically has been compared directly to sertraline in a randomized trial (Blumenthal 1999, Archives of Internal Medicine) with equivalent 16-week outcomes, with the exercise group showing lower relapse rates at 10-month follow-up.

If you want to assess your current muscle mass, grip strength, and functional capacity — and develop a personalized resistance training and nutritional protocol to preserve and build muscle for long-term health and longevity — a functional medicine evaluation including body composition testing and functional movement assessment provides the objective foundation for targeted intervention. Contact our office at (810) 206-1402 to schedule a consultation.

Muscle as an Endocrine Organ: Myokines, Sarcopenia, and Longevity